In April this year, the daughter of a 70 y/o man with prostate cancer emailed us. She reported her father, KG, had long-standing prostate enlargement which had been monitored closely. Then in November 2020, now a year ago, his PSA and alkaline phosphatase were markedly elevated - his PSA was 940 (over 4 is high) and his alkaline phosphatase 971(over 126 is high). This elevation in alk phos is the result of extensive bone metastases seen on his scan.
KG’s only other significant medical history is a stint, placed in 2018. Starting with the stint, he is prescribed BP lowering medications, a statin and Atenolol.
Lipid-bound Selenium, LbSe, was recommended in April, one dropper approximately every 12 hours. This dropper can be placed directly in the mouth, on bites of food or in the large end of a double 00 gelatin capsule.
Why LbSe? A simultaneous serum and red-blood-cell potassium, 4.3 and 94 respectively, indicates he is anabolic at the cell level. In anabolism, there is relatively more potassium inside cells compared to serum. In other words, there is an extra- to intracellular shift in potassium. Our man’s serum potassium is below 4.5 and his red-blood-cell potassium, RBC K, is greater than 90, indications he is anabolic on the cell level.
1 LbSe is catabolic on the cell level.
Further, his bone scan showed
lucent bone lesions. Lucent bone is less dense bone. Lucent bone lesions are anabolic lesions. Anabolic bone lesions are osteolytic, that is, bone is dissolved.
Descriptions of bone metastases on scan reports are extremely valuable and reliable. The scans of a woman with breast cancer and bone metastases this year specifically describe lytic lesions and “lytic destruction”. Although she is not able to get a RBC K, these scans are definitive for an anabolic off-balance in cells. She is responding positively to LbSe.
LbSe for KG yes, starting in April, and Lipid-bound Calcium, LbCa, was added a month later. Both are catabolic at the cell level. I chose LbCa also because his serum calcium was low, at 8.6. Since approximately one third of serum calcium is bound to albumin, a low albumin will decrease serum calcium. Therefore, it is important to note his albumin was normal at that time.
Dr. Revici found that the inability of anabolic cancers to utilize calcium favors their metastases. There is much more to say about LbCa that we will cover in another podcast.
When KG began LbSe in April, his alk phos had already decreased from last November’s 971 to 670. He had received two injections at the beginning of this year that decrease testosterone by antagonizing gonadotrophin-releasing hormones LH and FSH. Additionally, he took an androgen synthesis inhibitor daily and a monoclonal antibody used for bone metastases monthly.
Actually, KG’s drop in PSA was more dramatic than that of his alk phos. His PSA of 940 a year ago dropped to 21 per a test in May.
Then, on his August 30th lab, his alk phos and PSA are both normal!! We are all surprised, especially his urologist and oncologist. A decrease was expected, yes, but slowly, not precipitously and certainly not to normal.
Words of caution are warranted: we have never witnessed improvements in actual tumors from LbSe as described here for bone metastases, even when an extra- to intracellular shift of potassium has been documented. Since LbSe is used for cancers in conjunction with other therapies, improvements must be attributed to the protocol, not specifically to LbSe. Likewise, KG received medications aimed at reducing his cancer.
How does LbSe work? LbSe oxidizes leukotrienes, LTRs. LTRs are metabolites of arachidonic acid, AA. Dr. Revici identified a fatty acid in the 1930’s with three parallel double bonds that causes
irreversible damage. Other pro-inflammatory fatty acids do not. Appropriately, Dr. Revici called them
conjugated trienic fatty acids. They were renamed to leukotrienes 50 years later, around the time a Nobel Prize was awarded to a Swedish scientist, Samuelsson, for their discovery.
The certainty that LbSe oxidizes LTRs is strikingly evident in Dr. Revici’s successful management of opioid withdrawal with LbSe. LbSe literally extinguishes, and immediately, the severe insomnia, diarrhea, vomiting, bone and joint cramps and tremors of withdrawal, all due to LTRs.
The role of LTRs in bone metastases is well documented in an online article published just six months ago.
2 5-LOX, also known as 5-lipoxygenase, is the enzyme that converts AA to LTRs. This enzyme is overexpressed in tissue samples of patients with bladder, breast, esophageal, kidney, oral, pancreatic, and prostate cancer. Moreover, different types of LTRs have now been identified. Receptor expression of cysteinyl-leukotrienes negatively correlates with survival of patients with prostate, breast, and colon cancers. High levels of another LTR correlates with tumor aggressiveness in prostate cancer.
In recent decades, LTR receptor antagonists and synthesis inhibitors have been developed, often focused on the relief of bronchoconstriction in asthma. However, to date LTR modifiers, as they are called, are not as effective as corticosteroids or beta2 agonists plus steroids, in the management of asthma.
While LTRs are pro-inflammatory, even more so are the immune signaling molecules, cytokines, that LTRs release. Reports of cytokine storms, often deadly, led us to offer Lipid-bound Sulfur, LbS, for Covid-19 a year and a half ago. Respiratory symptoms lessened immediately and often symptoms completely resolved within 24 hours. Due to censorship, we no longer offer our protocol for Covid-19. Nevertheless, LbS might be a leukotriene modifier, actually a LTR eradicator, that mainstream investigators are seeking.
As LbSe alleviates opioid withdrawal by oxidizing LTRs, LbS successfully alleviates withdrawal from alcohol and tobacco by oxidizing LTRs. LbS has proven valuable in reducing the severity and duration of colds, bronchitis, sinusitis and flus, especially in conjunction with Flame Quell+ and glycerol. FQ+ and glycerol neutralize and therefore disable other pro-inflammatory eicosanoids. And note: LbS is invaluable in autoimmunity where LTRs and cytokines play a central role in irreversible tissue and cell damage.
I am available for consultations regarding use of Dr. Revici’s lipids in any case(s), with or without cancer, and regardless of diagnoses. Please call or email my office to schedule. And, we invite clinicians to join us in collecting data on the use of Dr. Revici’s lipids. A few clinicians have begun using LbS for long-haul covid. We will report their findings as soon as available.
Stay tuned, catabolic bone metastases comes next.
1.
https://drive.google.com/file/d/1AS9IjiTRZ2TwF56La9_cxLuY1Lt3l1gY/view 2.
https://jcmtjournal.com/article/view/4083#sec14